Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844999 · ClinicalTrials.gov registry record · NA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
A NA study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 392
- Enrollment target
- 4
- Study locations
NCT01844999: Completed NA study of Prostate Cancer, sponsored by Dana-Farber Cancer Institute.
NCT01844999 is a NA study of Prostate Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 392 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01844999, a NA study of Prostate Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 392 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.
Primary Outcome
O'Connor, 1995, Decisional conflict scale
Conditions Studied
Interventions
- BEHAVIORAL Personal Patient Profile - Prostate (P3P)
- BEHAVIORAL Standard prostate cancer information websites
Study Locations (4)
California
- Kaiser Permanente - Souther California - Downey
- Kaiser Permanente - Southern California - Los Angeles
Georgia
- Emory Healthcare - Atlanta
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 392 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2017-06-30 |
| Phase | NA |
What the finished NCT01844999 record still lists
NCT01844999 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Personal Patient Profile - Prostate (P3P) is the first listed.
NCT01844999 reports a single indexed study location in California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01844999 about?
NCT01844999 is a clinical study titled "Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks". The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.
What is the current status of trial NCT01844999?
This trial is currently completed. It is a NA study. The enrollment target is 392 participants. The study started on 2013-08-01. Estimated completion is 2017-06-30.
What conditions does trial NCT01844999 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01844999?
The interventions under investigation include: Personal Patient Profile - Prostate (P3P) (BEHAVIORAL), Standard prostate cancer information websites (BEHAVIORAL).
Who is sponsoring clinical trial NCT01844999?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01844999 being conducted?
This trial has 4 study locations across California, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01844999's enrollment target sits among peer trials
392 135th of 735 higher than 600 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06625775 · 392 participants · Phase 1
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- NCT07220967 · 392 participants · Phase 4
A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement
- NCT07290036 · 392 participants · Phase 1
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
- NCT05640999 · 393 participants · Phase 2
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI